Rifampicin Injection-Capsule Sequential Therapy for Retreatment Smear Positive Pulmonary Tuberculosis at Intensive Stage:Observation of Curative Effect
- VernacularTitle:利福平注射液-胶囊序贯治疗复治涂阳肺结核强化期的疗效观察
- Author:
Bo CHEN
- Publication Type:Journal Article
- Keywords:
Pulmonary tuberculosis(TB);
Chemotherapy;
Rifampicin
- From:
China Pharmacy
2007;0(26):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To observe the curative effect of Rifampicin Injection-Capsule sequential therapy for retreatment of smear positive pulmonary tuberculosis(TB) at intensive stage.METHODS: 80 patients with smear positive pulmonary tuberculosis at intensive stage were enrolled: 40(treatment group) were randomly assigned to receive HZES plus Rifampicin Injection-Capsule sequential therapy,and another 40(control group) to receive HZES plus Rifampicin capsule.Follow-up of sputum negative conversion rate,pulmonary lesion,and toxcity were scheduled at the end of first and second month during intensified stage.RESULTS: At the end of first and second month during intensified stage,the sputum negative conversion rates were 82.5% and 97.5% respectively in the treatment group versus 65.0% and 85.0% respectively in control gorup;the X-ray imaging test of chests revealed that the responsive rates were 17.5% and 40.0% in the treatment groups versus 10.0%and 25.0% in the control group.At the end of second month,the cavity closure(or diminution) rate was 41.7% in the treatment group versus 22.7% in the control group;the incidence of hepatic lesion was 22.5% verus 25.0% and that of gastrointestinal tract toxcity was 20.0% versus 45.0%.CONCLUSION: Rifampicin Injection-Capsule sequential therapy was proved to be of rapid onset of effect,remarkable efficacy,less toxicity and satisfactory efficacy in controlling symptom,shortening bacterial clearance time,reducing side effects and treating severe TB.
